HMGA2 (high mobility group AT-hook 2)
Written | 2000-05 | Florence Pedeutour |
Laboratoire de Génétique des Tumeurs Solides, 5ème étage, Faculté de Médecine, 28 avenue de Valombrose, 06107 Nice cedex 2, France | ||
Updated | 2005-12 | Karin Broberg |
Molecular biologist, Dep. of Occupational, Environmental Medicine, Lund University Hospital, SE-221 85 Lund, Sweden | ||
Updated | 2015-10 | Jian-Jun Wei |
Floyd Elroy Patterson Research Professor of Pathology, Department of Pathology and Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Women's Health Research Institute, 251 East Huron Street, Feinberg 7-334, Chicago, Illinois 60611; jianjun-wei@northwestern.edu |
Abstract | HMGA2, the High Mobility Group A2 gene, is a non-histone and architectural transcription factor. As an oncofetal protein, HMGA2 plays an important role in development and contributes to the tumorigenesis of many epithelial and mesenchymal tumors. Upregulation of HMGA2 by non-random chromosomal translocations is common in mesenchymal tumors, whereas by the altered transcription regulation is likely the major mechanism in malignant epithelial tumors and it involves much more complex mechanisms. HMGA2 directly and indirectly regulates the multiple biological and oncogenic pathways. Its oncogenic property remains to be fully characterized. |
Keywords | HMGA2, Development, miRNA regulation, Stem cell self-renewal, transcription regulation, Oncofetal protein, neoplasia, Aging and senescence, epithelial-to-mesenchymal transition (EMT), non-random chromosomal translocation. |
(Note : for Links provided by Atlas : click)
1. Identity
Alias_names | General Information |
high-mobility group (nonhistone chromosomal) protein isoform I-C | |
Alias_symbol (synonym) | BABL |
LIPO | |
Other alias | HMGIC (High mobility group protein isoform I-C |
STQTL9 | |
HGNC (Hugo) | HMGA2 |
LocusID (NCBI) | 8091 |
Atlas_Id | 82 |
Location | 12q14.3 [Link to chromosome band 12q14] |
Location_base_pair | Starts at 65824460 and ends at 65915527 bp from pter ( according to hg19-Feb_2009) [Mapping HMGA2.png] |
Local_order | telomeric to CDK4, centromeric to MDM2 |
![]() | |
FISH Probe(s) - Courtesy Mariano Rocchi | |
Fusion genes (updated 2017) | Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands) |
ACKR3 (2q37.3) / HMGA2 (12q14.3) | ALDH2 (12q24.12) / HMGA2 (12q14.3) | CCNB1IP1 (14q11.2) / HMGA2 (12q14.3) | |
COX6C (8q22.2) / HMGA2 (12q14.3) | EBF1 (5q33.3) / HMGA2 (12q14.3) | FHIT (3p14.2) / HMGA2 (12q14.3) | |
HMGA2 (12q14.3) / ACKR3 (2q37.3) | HMGA2 (12q14.3) / ALDH2 (12q24.12) | HMGA2 (12q14.3) / C9orf92 (9p22.3) | |
HMGA2 (12q14.3) / CACNB4 (2q23.3) | HMGA2 (12q14.3) / CCNB1IP1 (14q11.2) | HMGA2 (12q14.3) / CCT2 (12q15) | |
HMGA2 (12q14.3) / CHMP1A (16q24.3) | HMGA2 (12q14.3) / COG5 (7q22.3) | HMGA2 (12q14.3) / COX6C (8q22.2) | |
HMGA2 (12q14.3) / DYRK2 (12q15) | HMGA2 (12q14.3) / EBF1 (5q33.3) | HMGA2 (12q14.3) / EFCAB6 (22q13.2) | |
HMGA2 (12q14.3) / FHIT (3p14.2) | HMGA2 (12q14.3) / GRIP1 (12q14.3) | HMGA2 (12q14.3) / HMGA2 (12q14.3) | |
HMGA2 (12q14.3) / LARGE2 (11p11.2) | HMGA2 (12q14.3) / LHFPL6 (13q13.3) | HMGA2 (12q14.3) / LPP (3q28) | |
HMGA2 (12q14.3) / NFIB (9p23) | HMGA2 (12q14.3) / NUP107 (12q15) | HMGA2 (12q14.3) / PLPP3 (1p32.2) | |
HMGA2 (12q14.3) / RAD51B (14q24.1) | HMGA2 (12q14.3) / SETBP1 (18q12.3) | HMGA2 (12q14.3) / SOX5 (12p12.1) | |
HMGA2 (12q14.3) / VIPR1 (3p22.1) | HMGA2 (12q14.3) / WIF1 (12q14.3) | LHFPL6 (13q13.3) / HMGA2 (12q14.3) | |
LPP (3q28) / HMGA2 (12q14.3) | NFIB (9p23) / HMGA2 (12q14.3) | RAD51B (14q24.1) / HMGA2 (12q14.3) | |
WIF1 (12q14.3) / HMGA2 (12q14.3) |
2. DNA/RNA
![]() | |
HMGA2 has long UTR (about 3,000 nt). HMGA2 can be potentially regulated by multiple miRNAs and one of well characterized miRNAs is let-7 family which contains at least five predicted bindings sites. MIRLET7E (Let-7) repression of HMGA2 expression at transcription and translation has been demonstrated in several different studies (Lee and Dutta 2007, Wang et al. 2007, Peng et al. 2008). Inverse association of Let-7 and HMGA2 is an important regulation mechanism in normal development and abnormal tumorigensis (Park et al. 2007, Shell et al. 2007). | |
Description | 5 exons, spans approximately 160 kb; a sixth alternative terminal exon within intron 3 has been described |
Transcription | RNA: 4.1 kb. Transcription initiated from two different promoter regions. A polymorphic dinucleotide repeat upstream of the ATG start codon strongly regulates HMGA2 expression. Moreover, HMGA2 is controlled by negatively acting regulatory elements within the 3'UTR |
3. Protein
![]() | |
Description | 109 amino acids; three DNA binding domains (AT hooks) linked to the carboxy-terminal acidic domain that does not activate transcription. |
![]() | |
HMGA2 can directly regulate expression of many genes. Specific recognition of AT-rich DNA sequences by HMGA2 was reporte by a SELEX study. The relative heights are proportional to their frequencies shown in the 71 SELEX sequences (Cui and Leng 2007). | |
Expression | Fetal tissues: expression in various tissues, prominent in kidney, liver and uterus; adult tissues: no expression except in lung and kidney; tumors: expression in benign mesenchymal tumor tissues correlated to 12q15 rearrangements; expressed in malignant tumours (e.g., in breast tumours, pancreas tumours, ovarian cancer, lung tumours, colorectal cancer, nerve system tumours, oral cavity squamous cell cancer). |
![]() | |
Inverse expression pattern of HMGA2 and let-7 family in developmental and adulthood stages as well as neoplastic change (Park, Shell et al. 2007). | |
Localisation | nuclear |
![]() | |
Immunohistochemistry shows that HMGA2 is specifically expressed and located in nucleus. Photomicrographs illustrate strong immunoreactivity for HMGA2 in leiomyoma with t(12;14) translocation and high grade serous ovarian carcinoma (Wu and Wei 2013, Bertsch et al. 2014). | |
Function | Architectural factor, non histone, preferential binding to AT rich sequences in the minor groove of DNA helix; the precise function remains to be elucidated; probable role in regulation of cell proliferation. |
![]() | |
It is widely accepted that functional CDKN2A (p16INK4a) and RB1 (pRb) as well as the HMGA2, which accumulate at E2F target promoters during senescence, are critically required for SAHF arrangement (Narita et al. 2006). | |
Homology | Member of the HMGI protein family. |
![]() | |
HMGA2 is regulated by non-coding miRNAs and coding genes. As a non-histone nuclear transcription regulator, HMGA2 has a broad influence in many gene expression, mainly target at epithelial-to-mesenchymal transition (EMT), cell proliferation, DNA damage repair, stem cell self-renewal and differentiation, as well as tumorigenesis of many benign and malignant mesenchymal and epithelial tumors (Wu and Wei 2013). | |
![]() | |
HMGA2 regulates stem cell potential for self-renewal. HMGA2 seems to be a major regulator of INK4a/ARF expression. HMGA2 reduces INK4A and ARF expression. HMGA2 binds to the Junb locus. As JUNB promotes INK4A/ARF expression in stem cells, thus promoting stem cell self-renewal. Increase in let-7 expression results in the downregulation of HMGA2 and the derepression of the INK4a/ARF and activation of p16INK4a expression in self-renewing cells. In Hmga2-deficient mice, it shows reduced stem cell numbers and self-renewal. Furthermore, p16(Ink4a) and p19(Arf) expression were increased in Hmga2-deficient fetal and young-adult stem cells, and deletion of p16(Ink4a) and/or p19(Arf) partially restored self-renewal capacity. (Yu et al. 2007, Nishino et al. 2008). | |
4. Mutations
Germinal | Deletion of HMGIC in mutant mice or transgenic 'knock out' mice for the first two exons of HMGIC have the "pigmy" phenotype: low birth weight, craniofacial defects, adipocyte hypoplasia adult body weight about 40% of normal; mice with a partial or complete deficiency of HMGA2 resisted diet-induced obesity implicating a role of the gene in fat cell proliferation; truncations of mouse Hmga2 in transgenic mice result in somatic overgrowth and, in particular, increased abundance of fat and lipomas; overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituary adenomas secreting prolactic and growth hormone; HMGA2-null mice had very few spermatids and complete absence of spermatozoa. 8-year-old boy had a de novo pericentric inversion of chromosome 12, with breakpoints at p11.22 and q14.3. The phenotype included extreme somatic overgrowth, advanced endochondral bone and dental ages, a cerebellar tumour, and multiple lipomas. His chromosomal inversion was found to truncate HMGA2, which maps to the 12q14.3 breakpoint. |
5. Implicated in
Note | |
Entity | MESENCHYMAL BENIGN TUMORS as follows: |
Entity | Lipoma |
Disease | benign adipocyte tumor |
Prognosis | good |
Cytogenetics | various rearrangements involving 12q15 (translocations, inversions, deletions...); reciprocal translocations involve 12q15 with different partners such as chromosomes 1, 2, 3, 7, 10, 11, 13, 15, 17, 21, X; the most frequent anomaly is t(3;12)(q27-28;q15); cryptic rearrangements, such as paracentric inversions not detectable by conventional cytogenetics but detectable by FISH, have been described |
Hybrid/Mutated Gene | for t(3;12): HMGIC-LPP (LPP: lipoma preferred partner; 3q27-28); a gene located in 13q, LHFP (lipoma HMGIC fusion partner) was found to be fused with HMGIC in one case of lipoma; one lipoma displayed fusion of HMGA2 exon 4 with a sequence from intron 4, indicating abnormal splicing; HMGA2-CMKOR1 in three cases with aberrations involving 2q35-37 and 12q13-15; HMGA2-NFIB in one lipoma; |
Abnormal Protein | HMGIC-LPP; the three AT hook domains at the aminoterminal of HMGIC are fused to the LIM domain of LPP; another fusion protein due to the fusion of HMGIC with a putative gene located at 15q24 predicted to encode a protein with a serine/threonine-rich domain has also been described |
Oncogenesis | the relevance of the exact role LPP in the HMGA2-LPP fusion is not established yet, but the transactivation functions of the LPP LIM domains is retained in the fusion protein and the fusion protein can function as a transcription factor; the truncation of HMGA2 by itself may have a role in the tumorigenesis |
Entity | Uterine leiomyoma (uterine fibroids) |
Disease | benign mesenchymal tumors |
Prognosis | good |
Cytogenetics | approximately 40% of uterine leiomyomas have structural chromosomal rearrangements, about 10% of which involve 12q15 (translocations, inversions, deletions...); the most frequent anomaly is t(12;14)(q15;q23-24) |
Hybrid/Mutated Gene | in a majority of cases, there is no fusion gene: the breakpoint is located 10 kb up to 100 kb 5' to HMGIC; the recombinational repair gene RAD51B is a candidate to be the partner gene of HMGIC in t(12;14). In two cases (out of 81 primary tumors) exon 7 of RAD51B was fused in frame to either exon 2 or 3 of the HMGA2 gene; in one case with paracentric inversion, HMGIC exon 3 was fused to ALDH2 exon 13 (12q24.1); in one case (no cytogenetic analysis) HMGIC exon 3 was fused to COX6C 3' UTR (8q22-23); in one case, with apparently normal karyotype, exon 3 of HMGIC was fused to retrotransposon-like sequences RTVLH 3' LTRs; three fusion transcripts contained 3' cryptic exonic sequences present in intron 3 of the HMGA2 gene (breakpoints downstream of exons 3 or 4), suggesting that they are due to alternative splicing; one case displayed fusion of the first two exons of HMGA2 to the 3' portion of the CCNB1IP1/C14orf18/HEI10 gene |
![]() | |
Abnormal Protein | HMGIC-ALDH2: ALDH2 contribution was only 10 amino acids; |
Oncogenesis | HMGIC-ALDH2: it is suggested that the truncation of HMGIC, rather than fusion may be responsible for tumorigenesis; the 3' untranslated region may stabilize the HMGIC messenger RNA |
Entity | Pleomorphic adenoma of the salivary gland (or mixed salivary gland tumor) |
Disease | benign tumors from the major or minor salivary glands |
Prognosis | good |
Cytogenetics | approximately 12% of pleomorphic adenomas of salivary glands show abnormalities involving HMGIC in 12q15; the most frequent aberration is t(9;12)(p24.1;q15) |
Hybrid/Mutated Gene | in t(9;12): HMGIC-NFIB fusion; another type of fusion HMGIC-FHIT (3p14.2) has also been described |
Entity | Pulmonary chondroid hamartoma of the lung |
Disease | benign mesenchymal tumors of the lung |
Prognosis | good |
Cytogenetics | various rearrangements involving 12q15 leading to HMGIC dysregulation; cryptic rearrangements such as paracentric inversions not detectable by conventional cytogenetics but detectable by FISH have been described |
Hybrid/Mutated Gene | in two cases with apparently normal karyotypes, exon 3 of HMGIC was fused to retrotransposon-like sequences RTVLH 3' LTRs; in cases with t(3;12)(q27-28;q14-15) (see lipomas), a fusion of HMGA2-LPP was described; only 1/61 cases with normal karyotype displayed HMGA2-LPP fusion; three cases with rearrangements involving 12q14-15 and 13q12-14 lacked rearrangements of HMGA2-LHFP; |
![]() | |
Entity | Endometrial polyps |
Disease | uterine benign tumors |
Prognosis | good |
Cytogenetics | various rearrangements involving 12q15 leading to HMGIC dysregulation; cryptic rearrangements such as paracentric inversions not detectable by conventional cytogenetics but detectable by FISH have been described; in one case, HMGIC was amplified and overexpressed |
Entity | Myofibroblastic inflammatory tumor |
Disease | benign mesenchymal tumors |
Prognosis | good |
Cytogenetics | in one case, a complex rearrangement involving chromosomes 12 (in 12q15), 4 and 21 was described |
Hybrid/Mutated Gene | an aberrant transcript was produced by the fusion of HMGIC exon 3 to an ectopic sequence originating from the third intron of HMGIC |
Entity | Chondrolipoangioma |
Disease | a rare benign type of mesenchyomas composed predominantly of cartilage and adipose tissue with vascular elements and myxoid elements |
Cytogenetics | One case demonstrated t(12;15)(q13;q26). FISH analysis revealed rearrangement of chromosomes 2, 12 and 15 and HMGA2. |
Entity | Chondromas |
Disease | benign cartilage tumours |
Cytogenetics | HMGA2 was expressed in 4/6 soft tissue chondromas (all with 12q-rearrangements cytogenetically), three cases showed truncated (exons 1-3) transcripts, one case displayed a t(3;12)(q27;q15) and RT-PCR demonstrated a HMGA2-LPP fusion transcript composed of HMGA2 exons 1-3 and LPP exons 9-11. |
Entity | Hyaline vascular Castleman's disease |
Cytogenetics | one case with der(6)t(6;12)(q23;q15)del(12)(q15) is described. |
Hybrid/Mutated Gene | a combined immunologic-cytogenetic approach demonstrated HMGA2 rearrangement in follicular dendritic cells |
Entity | Prolactinoma |
Disease | prolactin-secreting pituary adenoma, non-metastasizing |
Cytogenetics | trisomy 12 nonrandom finding in pituary adenomas |
Hybrid/Mutated Gene | HMGA2 locus amplified in 7/8 prolactinomas |
Entity | Aggressive angiomyxoma of the vulva |
Disease | myxoid mesenchymal neoplasm |
Prognosis | infiltrative neoplasm, locally destructive recurrences, no metastatic potential |
Cytogenetics | one case displayed t(8;12)(p12;q15) |
Hybrid/Mutated Gene | FISH demonstrated a breakpoint 3' of the gene, the tumour expressed HMGA2 |
Entity | MALIGNANT TUMORS as follows: |
Entity | Well-differentiated liposarcoma |
Disease | malignant adipocyte tumor; peripheral or retroperitoneal location |
Prognosis | rather good; borderline malignancy; locally aggressive, rarely metastasizes |
Cytogenetics | supernumerary ring or giant marker chromosomes containing 12q14-15 amplification (surrounding MDM2); HMGIC is frequently amplified together with MDM2; rearrangement of HMGA2, in addition to amplification has been described |
Hybrid/Mutated Gene | ectopic sequences from 12q14-15, 1q24, 11q14, and chromosome 2 was shown to be fused to HMGA2 exon 2 or 3 |
Entity | Uterine leiomyosarcoma |
Disease | malignant counterpart of uterine leiomyoma |
Prognosis | poor |
Cytogenetics | 12q13-15 region is recurrently amplified |
Hybrid/Mutated Gene | HMGA2 amplified within this region |
Entity | Osteosarcoma |
Disease | malignant tumor |
Hybrid/Mutated Gene | in one osteosarcoma cell line (OsA-Cl) the three DNA binding domains of HMGIC fused to the keratan sulfate protein glycan gene LUM (12q22-23); LUM was fused out of frame, and only 3 amino acids were fused to HMGIC; in addition, the rearranged gene was amplified |
Entity | Myelofibrosis with myeloid metaplasia |
Disease | rare chronic myeloproliferative disorder |
Prognosis | variable |
Cytogenetics | one case with t(4;12)(q32;q15) and one case with t(5;12)(p14;q15) |
Hybrid/Mutated Gene | FISH analysis suggested breakpoint in HMGA2, RT-PCR revealed that HMGA2 is expressed in blood mononuclear cells from patients with this disease |
Entity | Acute lymphoblastic leukaemia |
Disease | Heterogenous disease that arises in precursor B or T cells |
Cytogenetics | One case with a t(9;12)(p22;q14), frequent deletions at 12q14.3 |
Hybrid/Mutated Gene | t(9;12): FISH analysis indicated a breakpoint in the 5' region of the gene, RT-PCR showed overexpression of HMGA2 lacking the carboxyterminal tail; deletions covering the 5' end of HMGA2 |
Entity | High-grade serous carcinoma of the fallopian tubes |
Disease | Serous carcinoma arising from fallopian tube secretory epithelia. |
Oncogenesis | Overexpression of HMGA2 regulated by several genetic mechanism, including CTNNB1 (β -Catenin), TGF- β, miRNAs. Currently well definied miRNAs including let-7 and MIR-182. MiR-182 promotes HMGA2 expression through negative regulation of BRCA1 (Moskwa et al. 2011, Liu et al. 2012). HMGA2 regulates several EMT genes including STC2 and LUM (Wu et al. 2011). Overexpression of HMGA2 is associated with early tumorigenesis, tumor cell proliferation, invasion and worse outcome through regulation of cell cycle, epithelial to mesenchymal transition (Wu et al. 2011). |
Entity | Pancreatic carcinoma |
Disease | Pancreatic ductal carcinoma. |
Oncogenesis | Overexpression of HMGA2 promote EMT by regulation of SNAIL, SLUG, SIP1, TCF3 (E12/E47), and ZEB1 (Watanabe et al. 2009). HMGA2 nuclear immunoreactivity correlates positively with lymph node metastases and high tumor grade (Hristov et al. 2009). |
Entity | Breast Cancer |
Disease | Serous carcinoma arising from fallopian tube secretory epithelia. |
Oncogenesis | HMGA2 gene and protein are highly expressed in metastatic breast cancer cells. HMGA2 as an important regulator of PAR1-mediated invasion. Inhibition of PAR1 signaling suppresses HMGA2-driven invasion in breast cancer cells (Yang et al. 2015). |
Entity | Colon Cancer |
Disease | Colonic adenocarcinoma. |
Oncogenesis | HMGA2 delays the clearance of H2AFX(γ-H2AX) in colon cancer. Overexpression of HMGA2 is associated with metastasis and unequivocally occurred in parallel with reduced survival rates of patients with colorectal carcinoma (Wang et al. 2011). |
Entity | Lung Cancer |
Disease | Non-small-cell lung cancer (NSCLC) |
Oncogenesis | HMGA2 can operate as competing endogenous RNA (ceRNA) for the let-7 microRNA (miRNA) family, suggesting that Hmga2 affects let-7 activity by altering miRNA targeting. HMGA2 promotes the transformation of lung cancer cells independent of protein-coding function. Tgfbr3 expression is regulated by the Hmga2 ceRNA through differential recruitment to Argonaute 2 (AGO2), and TGF-β signalling driven by Tgfbr3 is important for Hmga2 to promote lung cancer progression (Kumar et al. 2014). |
6. Breakpoints
![]() | |
Up to 21 partners have a breakpoint with HMGA2 are summarized. The majority of this non-random translocations were found to be in mesenchymal neoplasia (Wu and Wei 2013). | |
![]() | |
7. Bibliography
An increased high-mobility group A2 expression level is associated with malignant phenotype in pancreatic exocrine tissue. |
Abe N, Watanabe T, Suzuki Y, Matsumoto N, Masaki T, Mori T, Sugiyama M, Chiappetta G, Fusco A, Atomi Y |
British journal of cancer. 2003 ; 89 (11) : 2104-2109. |
PMID 14647145 |
High mobility group I-C protein in astrocytoma and glioblastoma. |
Akai T, Ueda Y, Sasagawa Y, Hamada T, Date T, Katsuda S, Iizuka H, Okada Y, Chada K |
Pathology, research and practice. 2004 ; 200 (9) : 619-624. |
PMID 15497774 |
In vivo modulation of Hmgic reduces obesity. |
Anand A, Chada K |
Nature genetics. 2000 ; 24 (4) : 377-380. |
PMID 10742101 |
Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. |
Andrieux J, Demory JL, Dupriez B, Quief S, Plantier I, Roumier C, Bauters F, Laï JL, Kerckaert JP |
Genes, chromosomes & cancer. 2004 ; 39 (1) : 82-87. |
PMID 14603445 |
Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. |
Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ |
The Journal of biological chemistry. 2000 ; 275 (19) : 14394-14400. |
PMID 10747931 |
Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. |
Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K |
Cell. 1995 ; 82 (1) : 57-65. |
PMID 7606786 |
MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. |
Bertsch, E., W. Qiang, Q. Zhang, M. Espona-Fiedler, S. Druschitz, Y. Liu, K. Mittal, B. Kong, T. Kurita and J. J. Wei |
Mod Pathol (2014).27(8): 1144-1153 |
PMID 4081525 |
Human HMGA2 promoter is coregulated by a polymorphic dinucleotide (TC)-repeat. |
Borrmann L, Seebeck B, Rogalla P, Bullerdiek J |
Oncogene. 2003 ; 22 (5) : 756-760. |
PMID 12569368 |
Fusion of RDC1 with HMGA2 in lipomas as the result of chromosome aberrations involving 2q35-37 and 12q13-15. |
Broberg K, Zhang M, Strömbeck B, Isaksson M, Nilsson M, Mertens F, Mandahl N, Panagopoulos I |
International journal of oncology. 2002 ; 21 (2) : 321-326. |
PMID 12118328 |
HMGA molecules in neuroblastic tumors. |
Cerignoli F, Ambrosi C, Mellone M, Assimi I, di Marcotullio L, Gulino A, Giannini G |
Annals of the New York Academy of Sciences. 2004 ; 1028 : 122-132. |
PMID 15650238 |
HMGA1 and HMGA2 protein expression in mouse spermatogenesis. |
Chieffi P, Battista S, Barchi M, Di Agostino S, Pierantoni GM, Fedele M, Chiariotti L, Tramontano D, Fusco A |
Oncogene. 2002 ; 21 (22) : 3644-3650. |
PMID 12032866 |
Array comparative genomic hybridization analysis of uterine leiomyosarcoma. |
Cho YL, Bae S, Koo MS, Kim KM, Chun HJ, Kim CK, Ro DY, Kim JH, Lee CH, Kim YW, Ahn WS |
Gynecologic oncology. 2005 ; 99 (3) : 545-551. |
PMID 16125217 |
Hyaline vascular Castleman's disease with HMGIC rearrangement in follicular dendritic cells: molecular evidence of mesenchymal tumorigenesis. |
Cokelaere K, Debiec-Rychter M, De Wolf-Peeters C, Hagemeijer A, Sciot R |
The American journal of surgical pathology. 2002 ; 26 (5) : 662-669. |
PMID 11979097 |
Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. |
Crombez KR, Vanoirbeek EM, Van de Ven WJ, Petit MM |
Molecular cancer research : MCR. 2005 ; 3 (2) : 63-70. |
PMID 15755872 |
Specific recognition of AT-rich DNA sequences by the mammalian high mobility group protein AT-hook 2: a SELEX study. |
Cui, T. and F. Leng |
Biochemistry (2007).46(45): 13059-13066 |
PMID 17956125 |
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. |
Cycle Park, S. M., S. Shell, A. R. Radjabi, R. Schickel, C. Feig, B. Boyerinas, D. M. Dinulescu, E. Lengyel and M. E. Peter |
Cell (2007).6(21): 2585-2590 |
PMID 17957144 |
Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. |
Dahlén A, Mertens F, Rydholm A, Brosjö O, Wejde J, Mandahl N, Panagopoulos I |
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2003 ; 16 (11) : 1132-1140. |
PMID 14614053 |
The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. |
Dev Lee, Y. S. and A. Dutta |
Genes (2007).21(9): 1025-1030 |
PMID 1855228 |
Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. |
Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, Fusco A |
Oncogene. 2002 ; 21 (20) : 3190-3198. |
PMID 12082634 |
The High Mobility Group A2 gene is amplified and overexpressed in human prolactinomas. |
Finelli P, Pierantoni GM, Giardino D, Losa M, Rodeschini O, Fedele M, Valtorta E, Mortini P, Croce CM, Larizza L, Fusco A |
Cancer research. 2002 ; 62 (8) : 2398-2405. |
PMID 11956103 |
HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. |
Gattas GJ, Quade BJ, Nowak RA, Morton CC |
Genes, chromosomes & cancer. 1999 ; 25 (4) : 316-322. |
PMID 10398424 |
Sequencing of intron 3 of HMGA2 uncovers the existence of a novel exon. |
Hauke S, Flohr AM, Rogalla P, Bullerdiek J |
Genes, chromosomes & cancer. 2002 ; 34 (1) : 17-23. |
PMID 11921278 |
Chromosomal rearrangements leading to abnormal splicing within intron 4 of HMGIC? |
Hauke S, Rippe V, Bullerdiek J |
Genes, chromosomes & cancer. 2001 ; 30 (3) : 302-304. |
PMID 11170289 |
Chromosomal translocations in benign tumors: the HMGI proteins. |
Hess JL |
American journal of clinical pathology. 1998 ; 109 (3) : 251-261. |
PMID 9495195 |
HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. |
Hristov, A. C., L. Cope, M. D. Reyes, M. Singh, C. Iacobuzio-Donahue, A. Maitra and L. M. Resar |
Mod Pathol (2009).22(1): 43-49 |
PMID 2769577 |
HMGA proteins in malignant peripheral nerve sheath tumor and synovial sarcoma: preferential expression of HMGA2 in malignant peripheral nerve sheath tumor. |
Hui P, Li N, Johnson C, De Wever I, Sciot R, Manfioletti G, Tallini G |
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2005 ; 18 (11) : 1519-1526. |
PMID 16056249 |
Inflammatory myofibroblastic tumor with HMGIC rearrangement. |
Kazmierczak B, Dal Cin P, Sciot R, Van den Berghe H, Bullerdiek J |
Cancer genetics and cytogenetics. 1999 ; 112 (2) : 156-160. |
PMID 10686944 |
Amplification of a rearranged form of the high-mobility group protein gene HMGIC in OsA-CI osteosarcoma cells. |
Kools PF, Van de Ven WJ |
Cancer genetics and cytogenetics. 1996 ; 91 (1) : 1-7. |
PMID 8908160 |
HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. |
Kumar, M. S., E. Armenteros-Monterroso, P. East, P. Chakravorty, N. Matthews, M. M. Winslow and J. Downward |
Nature (2014).505(7482): 212-217 |
PMID 3886898 |
Three aberrant splicing variants of the HMGIC gene transcribed in uterine leiomyomas. |
Kurose K, Mine N, Iida A, Nagai H, Harada H, Araki T, Emi M |
Genes, chromosomes & cancer. 2001 ; 30 (2) : 212-217. |
PMID 11135440 |
Expression of the HMGA2-LPP fusion transcript in only 1 of 61 karyotypically normal pulmonary chondroid hamartomas. |
Lemke I, Rogalla P, Grundmann F, Kunze WP, Haupt R, Bullerdiek J |
Cancer genetics and cytogenetics. 2002 ; 138 (2) : 160-164. |
PMID 12505264 |
Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. |
Ligon AH, Moore SD, Parisi MA, Mealiffe ME, Harris DJ, Ferguson HL, Quade BJ, Morton CC |
American journal of human genetics. 2005 ; 76 (2) : 340-348. |
PMID 15593017 |
MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. |
Liu, Z., J. Liu, M. F. Segura, C. Shao, P. Lee, Y. Gong, E. Hernando and J. J. Wei |
J Pathol (2012).228(2): 204-215 |
PMID 22322863 |
Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions. |
Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O |
Genes, chromosomes & cancer. 2001 ; 31 (3) : 264-273. |
PMID 11391797 |
Fusion of a sequence from HEI10 (14q11) to the HMGIC gene at 12q15 in a uterine leiomyoma. |
Mine N, Kurose K, Konishi H, Araki T, Nagai H, Emi M |
Japanese journal of cancer research : Gann. 2001 ; 92 (2) : 135-139. |
PMID 11223542 |
Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. |
Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K |
Cancer research. 2004 ; 64 (6) : 2024-2029. |
PMID 15026339 |
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. |
Moskwa, P., F. M. Buffa, Y. Pan, R. Panchakshari, P. Gottipati, R. J. Muschel, J. Beech, R. Kulshrestha, K. Abdelmohsen, D. M. Weinstock, M. Gorospe, A. L. Harris, T. Helleday and D. Chowdhury |
Mol Cell (2011).41(2): 210-220 |
PMID 3249932 |
A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. |
Narita, M., V. Krizhanovsky, S. Nunez, A. Chicas, S. A. Hearn, M. P. Myers and S. W. Lowe |
Cell (2006).126(3): 503-514 |
PMID 1690178 |
Fusion of the HMGA2 and NFIB genes in lipoma. |
Nilsson M, Panagopoulos I, Mertens F, Mandahl N |
Virchows Archiv : an international journal of pathology. 2005 ; 447 (5) : 855-858. |
PMID 16133369 |
Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. |
Nishino, J., I. Kim, K. Chada and S. J. Morrison |
Cell (2008).135(2): 227-239 |
PMID 2582221 |
Chromosomal translocation t(8;12) induces aberrant HMGIC expression in aggressive angiomyxoma of the vulva. |
Nucci MR, Weremowicz S, Neskey DM, Sornberger K, Tallini G, Morton CC, Quade BJ |
Genes, chromosomes & cancer. 2001 ; 32 (2) : 172-176. |
PMID 11550285 |
Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia. |
Patel HS, Kantarjian HM, Bueso-Ramos CE, Medeiros LJ, Haidar MA |
Genes, chromosomes & cancer. 2005 ; 42 (1) : 87-94. |
PMID 15495192 |
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. |
Peng, Y., J. Laser, G. Shi, K. Mittal, J. Melamed, P. Lee and J. J. Wei |
Mol Cancer Res (2008).6(4): 663-673 |
PMID 18403645 |
LPP, the preferred fusion partner gene of HMGIC in lipomas, is a novel member of the LIM protein gene family. |
Petit MM, Mols R, Schoenmakers EF, Mandahl N, Van de Ven WJ |
Genomics. 1996 ; 36 (1) : 118-129. |
PMID 8812423 |
HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. |
Pierantoni GM, Santulli B, Caliendo I, Pentimalli F, Chiappetta G, Zanesi N, Santoro M, Bulrich F, Fusco A |
International journal of oncology. 2003 ; 23 (2) : 363-367. |
PMID 12851685 |
Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. |
Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC |
Cancer research. 2003 ; 63 (6) : 1351-1358. |
PMID 12649198 |
The t(3;12)(q27;q14-q15) with underlying HMGIC-LPP fusion is not determining an adipocytic phenotype. |
Rogalla P, Kazmierczak B, Meyer-Bolte K, Tran KH, Bullerdiek J |
Genes, chromosomes & cancer. 1998 ; 22 (2) : 100-104. |
PMID 9598796 |
Absence of HMGIC-LHFP fusion in pulmonary chondroid hamartomas with aberrations involving chromosomal regions 12q13 through 15 and 13q12 through q14. |
Rogalla P, Lemke I, Bullerdiek J |
Cancer genetics and cytogenetics. 2002 ; 133 (1) : 90-93. |
PMID 11890997 |
Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. |
Schoenberg Fejzo M, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremowicz S, Yoon SJ, Kucherlapati RS, Chada K, Morton CC |
Genes, chromosomes & cancer. 1996 ; 17 (1) : 1-6. |
PMID 8889500 |
Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. |
Schoenmakers EF, Huysmans C, Van de Ven WJ |
Cancer research. 1999 ; 59 (1) : 19-23. |
PMID 9892177 |
Let-7 expression defines two differentiation stages of cancer. |
Shell, S., S. M. Park, A. R. Radjabi, R. Schickel, E. O. Kistner, D. A. Jewell, C. Feig, E. Lengyel and M. E. Peter |
Proc Natl Acad Sci U S A (2007).104(27): 11400-11405 |
PMID 2040910 |
Evidence for RAD51L1/HMGIC fusion in the pathogenesis of uterine leiomyoma. |
Takahashi T, Nagai N, Oda H, Ohama K, Kamada N, Miyagawa K |
Genes, chromosomes & cancer. 2001 ; 30 (2) : 196-201. |
PMID 11135437 |
Translocation of the HMGI-C ( HMGA2) gene in a benign mesenchymoma (chondrolipoangioma). |
Van Dorpe J, Dal Cin P, Weremowicz S, Van Leuven F, de Wever I, Van den Berghe H, Fletcher CD, Sciot R |
Virchows Archiv : an international journal of pathology. 2002 ; 440 (5) : 485-490. |
PMID 12021922 |
A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. |
Wang, T., X. Zhang, L. Obijuru, J. Laser, V. Aris, P. Lee, K. Mittal, P. Soteropoulos and J. J. Wei |
Genes Chromosomes Cancer (2007).46(4): 336-347 |
PMID 17243163 |
Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers. |
Wang, X., X. Liu, A. Y. Li, L. Chen, L. Lai, H. H. Lin, S. Hu, L. Yao, J. Peng, S. Loera, L. Xue, B. Zhou, L. Zhou, S. Zheng, P. Chu, S. Zhang, D. K. Ann and Y. Yen |
Clin Cancer Res (2011).17(8): 2570-2580 |
PMID 3079060 |
Hidden paracentric inversions of chromosome arm 12q affecting the HMGIC gene. |
Wanschura S, Dal Cin P, Kazmierczak B, Bartnitzke S, Van den Berghe H, Bullerdiek J |
Genes, chromosomes & cancer. 1997 ; 18 (4) : 322-323. |
PMID 9087575 |
HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. |
Watanabe, S., Y. Ueda, S. Akaboshi, Y. Hino, Y. Sekita and M. Nakao |
Am J Pathol (2009).174(3): 854-868 |
PMID 2665746 |
HMGA2 and high-grade serous ovarian carcinoma. |
Wu, J. and J. J. Wei |
J Mol Med (Berl). 2013 Oct;91(10):1155-65 |
PMID 23686260 |
HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. |
Wu, J., Z. Liu, C. Shao, Y. Gong, E. Hernando, P. Lee, M. Narita, W. Muller, J. Liu and et al. |
Cancer Research (2011).71(2): 349-359 |
PMID 21224353 |
Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. |
Yang, E., J. Cisowski, N. Nguyen, K. O'Callaghan, J. Xu, A. Agarwal, A. Kuliopulos and L. Covic |
Oncogene (2015). |
PMID 26165842 |
let-7 regulates self renewal and tumorigenicity of breast cancer cells. |
Yu, F., H. Yao, P. Zhu, X. Zhang, Q. Pan, C. Gong, Y. Huang, X. Hu, F. Su, J. Lieberman and E. Song |
Cell (2007).131(6): 1109-1123 |
PMID 18083101 |
Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. |
Zhou X, Benson KF, Ashar HR, Chada K |
Nature. 1995 ; 376 (6543) : 771-774. |
PMID 7651535 |
8. Citation
This paper should be referenced as such : |
Jian-Jun Wei |
HMGA2 (high mobility group AT-hook 2) |
Atlas Genet Cytogenet Oncol Haematol. 2016;20(7):403-412. |
Free journal version : [ pdf ] [ DOI ] |
On line version : http://atlasgeneticsoncology.usal.es/classic/Genes/HMGICID82.html |
History of this paper: |
Pedeutour, F. HMGIC (high mobility group protein isoform I-C). Atlas Genet Cytogenet Oncol Haematol. 2000;4(2):64-67. |
http://documents.irevues.inist.fr/bitstream/handle/2042/37615/05-2000-HMGICID82.pdf |
Broberg, K. HMGA2 (high mobility group AT-hook 2). Atlas Genet Cytogenet Oncol Haematol. 2006;10(3):142-148. |
http://documents.irevues.inist.fr/bitstream/handle/2042/38311/12-2005-HMGICID82.pdf |
9. Other Leukemias implicated (Data extracted from papers in the Atlas) [ 8 ]
Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 15 ] |
Other Cancer prone implicated (Data extracted from papers in the Atlas) [ 1 ] |
Proteus syndrome |
10. External links
REVIEW articles | automatic search in PubMed |
Last year publications | automatic search in PubMed |
© Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Thu Jan 17 18:57:16 CET 2019 |
For comments and suggestions or contributions, please contact us atlasgeneticsoncology@usal.es.